Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(18 sites)
France
Centre Hospitalier d'Avignon, Avignon Lyon - Centre Léon Bérard, Lyon Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola Instituto Europeo di Oncologia (IEO), Milan Santa Maria della Misericordia Hospital, Perugia AULSS2 Marca Trevigiana Treviso, Treviso Spain
Complejo Hospitalario Universitario a Coruña, A Coruña Complejo Hospitalario de Jaén, Jaén Hospital Universitario Puerta de Hierro, Madrid Switzerland
Kantonsspital Baden, Baden University Hospital Basel, Basel Kantonsspital St. Gallen, Sankt Gallen Centre Hospitalier du Valais Romand, Sion Bürgerspital Solothurn, Solothurn Kantonsspital Winterthur, Winterthur Last updated February 2026